source
- Experts discuss real-world evidence and research gaps in metastatic castration-sensitive prostate cancerIndustry and academic experts gathered to examine how real-world evidence can be used to compare treatments for metastatic castration-sensitive prostate cancer. They highlighted the strengths and l…
- Zanidatamab shows strong single-agent activity in HER2-positive gastric and biliary cancersZanidatamab, a dual HER2-binding antibody, demonstrated notable efficacy as a single agent in studies of gastric and biliary tract cancers. The activity was described as striking, suggesting that…